At the news
? NEUTRALIMPACT 4/10 8-K filed Aug 31, 2026 at 15:54 ET
BridgeBio announced a voluntary agreement with the U.S. government to lower drug costs and expand Medicaid access to its marketed medicine Attruby, with no future pricing mandates expected. The specific terms are confidential, but the deal excludes medicines approved exclusively for orphan indications and has no impact on the company's existing copay assistance program.
- Voluntary agreement with U.S. government to lower drug costs and expand Medicaid access to Attruby via the GENEROUS Model
- BridgeBio expects no future pricing mandates under this agreement
- Pricing commitments exclude medicines approved exclusively for orphan indications
- Attruby will continue to be offered via Medicare Part D without future pricing mandates
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access